

SOFIA R BARTLETT - CV

Sofia R Bartlett

Senior Scientist & Adjunct Professor

British Columbia Centre for Disease Control & University of British Columbia

Contact: Address: 655 West 12th Avenue, Vancouver, BC V6Z 2R3 Canada
Office phone: +1-604-707-2434
Email: sofia.bartlett@bccdc.ca

Citizenship: Australian citizen by birth & Canadian permanent resident since 2020

CAREER SUMMARY

[LinkedIn.com/sofiabartlett88/](https://www.linkedin.com/sofiabartlett88/)

- ◆ Early career researcher experienced in infectious disease epidemiology, implementation science, and use of linked administrative health data platforms for public health surveillance, program monitoring, evaluation, and research.
- ◆ Nine years' combined experience working in academic and public health settings on research, surveillance, programming, monitoring and evaluation related to sexually transmitted and blood-borne infections (STBBIs) and substance use related harms.
- ◆ My focus is on research that will lead to findings which can be applied to better inform and design public health interventions and policies, with an emphasis on health equity.
- ◆ 37 peer-reviewed scientific publications; 12 first author, 2 senior author and 23 additional co-authored papers
- ◆ Sought after speaker and commentator, with more than 50 presented conference abstracts, 23 invited presentations and 12 published media interviews and blog posts

EDUCATION

2018 - 2021 Postdoctoral Fellowship, University of British Columbia, Vancouver, Canada
2013 - 2017 Doctor of Philosophy (Medicine), University of New South Wales Australia
2007 -2010 Bachelor of Science (Honours), James Cook University Australia

AWARDS & RECOGNITIONS

(16 total)

2021 15th Academic and Health Policy Conference on Correctional Health Early Career Investigator Scholarship (\$450 USD)
2020 Canadian Liver Meeting Young Investigator Award (\$1500 CAD)
2019 European Association for the Study of the Liver Young Investigator Full Conference Bursary (€950 EUR)
2019 Canadian Association for the Study of the Liver Postdoctoral Fellow Full Conference Bursary (\$1000 CAD)
2019 University of British Columbia Faculty of Medicine Postdoctoral Fellow Travel Bursary (\$1000 CAD)
2017 Australian Centre for Hepatitis Virology Chris Burrell hepatitis C virus International Travel Award (\$4,000 AUD)
2017 Amplify Ignite PhD Pitch Competition People's Choice Winner (\$1,000 AUD)
2016 The Layne Beachley Foundation Aim For The Stars Scholarship (\$4,000 AUD)

SOFIA R BARTLETT - CV

- 2016 University of New South Wales Postgraduate Council Postgraduate Research Student Award
- 2016 Australian Centre for Hepatitis Virology Young Investigator Conference Bursary (\$1000 AUD)
- 2016 University of New South Wales 3 Minute Thesis Medicine Faculty Winner (\$500 AUD)
- 2016 British Council Australia FameLab New South Wales Finalist
- 2015 Australian Centre for Hepatitis Virology Doherty Institute Educational Grant (Hepatitis) (\$500 AUD)
- 2015 University of New South Wales Postgraduate Research Student Support Travel Scholarship (\$2,600 AUD)
- 2014 University of New South Wales 3 Minute Thesis Medicine Faculty People's Choice Winner (\$250 AUD)
- 2014 Australian Centre for Hepatitis Virology Early Career Researcher International Travel Award (\$4,000 AUD)

PROFESSIONAL EXPERIENCE & APPOINTMENTS

- 2021 – Current** **Senior Scientist;** Sexually Transmitted & Blood-Borne Infections, Clinical Prevention Services, [British Columbia Centre for Disease Control](#), Vancouver, Canada
- Lead design, conduct and interpretation of public health research, surveillance, monitoring and evaluation addressing gaps in knowledge around viral hepatitis, HIV and STIs in British Columbia & Canada. Oversee development and preparation of grant proposals, ethics proposals, scientific/technical reports, academic publications, and lay reports. Mentor, train and supervise research staff, students and trainees, and collaborate with community, industry and government stakeholders in the development and execution of analyses and evaluations of public health importance.
- 2021 – Current** **Adjunct Professor;** [School of Population & Public Health](#), Faculty of Medicine, University of British Columbia, Vancouver, Canada
- Member of Epidemiology, Biostatistics and Public Health Division. Contribute to School Committees, teaching and research.
- 2021 – Current** **Investigator;** [Canadian Institute of Health Research \(CIHR\) Canadian HIV Trials Network \(CTN\)](#)
- Member of Co-infections and Related Conditions (CRC) research core. Conduct research aligned with CTN CRC goals of improving the prevention, diagnosis, management and treatment of HIV, HCV and other STBBIs and emerging co-infections and their related health impacts
- 2021 – Current** **Investigator;** [Canadian Network on Hepatitis C](#) (CanHepC)
- Conduct research aligned with CanHepC Research Area 1: Optimising prevention and treatment programs to eliminate hepatitis C.
- 2018 – 2021** **Postdoctoral Fellow;** Hepatitis Clinical Prevention Services, British Columbia Centre for Disease Control & University of British Columbia, Vancouver, Canada
- Designed, conducted and interpreted public health research addressing gaps in knowledge around viral hepatitis, HIV, STIs and COVID-19 in British Columbia,

SOFIA R BARTLETT - CV

Canada. Acquired information related to emerging public health issues through identification of existing datasets that were accessed or linked, deployed surveys, and developed of new proxy flags/algorithms for linked admin data. Developed and prepared grant proposals, ethics proposals, scientific/technical reports, academic publications, and lay reports

2018- 2020

Adjunct Associate Lecturer; Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW, Australia

Designed, conducted and interpreted public health research addressing gaps in knowledge around viral hepatitis, HIV and STIs in Australia and Papua New Guinea. Prepared academic grant proposals, ethics proposals, scientific and academic reports and publications, and lay reports.

2017 – 2018

Research Assistant; Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW, Australia

Designed, conducted and interpreted public health research addressing gaps in knowledge around viral hepatitis in correctional settings. Prepared academic grant proposals, scientific publications, and lay reports.

2016 – 2017

Intern; HIV, Hepatitis and Sexually Transmitted Infections Unit, Western Pacific Regional Office, World Health Organisation, Manila, Philippines

Coordinated data collection and visualization for Western Pacific Region HIV surveillance database. Coordinated and convened Western Pacific Region Viral Hepatitis Laboratory Testing and Surveillance Network Terms of Reference working group. Created viral hepatitis educational materials for laboratory and surveillance professionals. Prepared academic grant proposals and lay reports.

2011 – 2013

Research Assistant; Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia

Planned and carried out laboratory based scientific research and development of diagnostic assays for detection of mixed hepatitis C virus infection, hepatitis C virus genome sequencing, and human genetic polymorphism determination. Managed large clinical specimen biobank and developed SOPs for sample receipt and cataloguing. Project management of bio specimen collection for international clinical trials.

PEER-REVIEWED, AUTHORED PUBLICATIONS

(37 total; 12 [first author](#) & 2 [senior author](#))

1. Jeong D, Adu P, Binka M, Mahmood B, Buller-Taylor T, Damascene MJ, Iyaniwura S, Iyaniwura S, Ringa N, Velasquez H, Wong S, Yu A, **Bartlett S**, Wilton J, Irvine M, Otterstatter M, Janjua NZ. "Cohort profile: the British Columbia COVID-19 population mixing patterns survey (BC-Mix)". Accepted in BMJ Open, July 2022.
2. [Bartlett SR](#), Verich A, Finlayson R, Baker D, Bloch M, Doyle J, Shaw D, Hajkovicz K, Read P, Hellard M, Filep E, Yee J, Martinez M, Lamoury FMJ, Lin L, Dore GJ, Matthews GV, Applegate T, Martinello M. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct acting antiviral era: a molecular epidemiology study among participants in the CEASE cohort. Accepted in Health Science Reports, June 2022.
3. [Bartlett S](#), Tiwana A, Dhillon D. 'Sexually Transmitted and Blood-Borne Infection testing and linkage to care during incarceration: there's no time like the prison time!'. University of British Columbia Medical Journal 2022;13(2):10-12.

SOFIA R BARTLETT - CV

4. Makuza JD, Jeong D, Soe, P, **Bartlett S**, Velásquez García H, Binka M, Adu P, Dushimiyimana D, Dushimiyimana V, Maliza C, Nisingizwe M, Rwibasira G, Tuyishime A, Janjua N. Impact of COVID-19 pandemic on HCV Care cascade in Rwanda: Ecological study from July 2019 to June 2021. *Clinical Liver Disease* 2022;20:25–30. DOI: [10.1002/cld.1235](https://doi.org/10.1002/cld.1235)
5. Yazdani K, Dolguikh K, Zhang W, Shayeginik S, Ly J, Cooper S, Trigg J, **Bartlett S**, Barrios R, Montaner J, Salters K. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. *PLoS ONE* 2022;17(3):e0265811. DOI: [10.1371/journal.pone.0265811](https://doi.org/10.1371/journal.pone.0265811)
6. Nikiforuk AM, McMillan B, **Bartlett SR**, Márquez AC, Pidduck T, Kustra J, Goldfarb DM, Barakauskas V, Sinclair G, Patrick DM, Sadarangani M, Ogilvie GS, Morshed M, Sekirov I, Jassem AN. Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Measure SARS-CoV-2 Humoral Immunogenicity. *Microbiology Spectrum* 2022;10(2):e01405-21. DOI: [10.1128/spectrum.01405-21](https://doi.org/10.1128/spectrum.01405-21)
7. Cholette F, Mesa C, Harris A, Ellis H, Cachero K, Lacap P, Galipeau Y, Langlois MA, Gingras AC, Yansouni CP, Papenburg J, Cheng MP, Chakraborty P, Stein DR, Van Caesele P, **Bartlett S**, Kraiden M, Goldfarb D, McGeer A, Osiowy C, Hankins C, Mazer B, Drebot M, Kim J, on behalf of the Canadian Immunity Task Force (CITF) working group. Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. *PLOS ONE* 16(12): e0261003. DOI: [10.1371/journal.pone.0261003](https://doi.org/10.1371/journal.pone.0261003)
8. Wilton J, Wong S, Purssell R, Abdia Y, Chong M, Karim ME, MacInnes A, **Bartlett SR**, Balshaw RF, Gomes T, Yu A, Alvarez M, Dart RC, Kraiden M, Buxton JA, Janjua NZ. Association between prescription opioid therapy for non-cancer pain and hepatitis C virus seroconversion: A retrospective administrative study. *JAMA Netw Open*. 2022;5(1): e2143050. DOI: [10.1001/jamanetworkopen.2021.43050](https://doi.org/10.1001/jamanetworkopen.2021.43050)
9. Harland K, Richards H, Bonn M, Materniak S, **Bartlett S**. The need for evidence-based harm reduction services in correctional facilities during the COVID-19 pandemic. Accepted in *Journal of Prisoners on Prisons*, December 2021.
10. Binka M, **Bartlett S**, Velasquez H, Darvishian M, Jeong D, Prince A, Alvarez M, Wong S, Yu A, Samji H, Kraiden M, Wong J, Janjua NZ. Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: an interrupted time series analysis. *Liver International*, 2021. DOI: [10.1111/liv.15074](https://doi.org/10.1111/liv.15074)
11. Pearce M, Yu A, **Bartlett S**, Reitz C, Currie E, Westerby J, Jefferies H, Madsen J, Lamb J, Wilton J, Adu P, Clementi E, Wong S, Samji H, Alvarez M, Wong J, Kraiden M, Janjua Z. Women in the 2019 hepatitis C cascade of care: Findings from the British Columbia Hepatitis Testers Cohort Study. *BMC Women's Health*, 2021. DOI: [10.1186/s12905-021-01470-7](https://doi.org/10.1186/s12905-021-01470-7)
12. Harney BL, Korchinski M, Young P, Scow M, Jack K, Linsley P, Bodkin C, Brothers TD, Curtis M, Higgs P, Mead TS, Hart A, Kilroy D, Bonn M, **Bartlett SR**. It is time for us all to embrace person-centred language for people in prison and people who were formerly in prison. *International Journal of Drug Policy*, 2021. DOI: [10.1016/j.drugpo.2021.103455](https://doi.org/10.1016/j.drugpo.2021.103455)
13. **Bartlett SR**, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Kraiden M, Janjua NZ. The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study. *Clinical Infectious Diseases*, 2021 DOI: [10.1093/cid/ciab546](https://doi.org/10.1093/cid/ciab546)
14. Jeong D, Karim E, Wong S, Wilton J, Butt Z, Binka M, Adu P, **Bartlett S**, Pearce M, Clementi E, Yu A, Alvarez M, Samji H, Velasquez H, Abdia Y, Kraiden M, Janjua N. Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. Accepted in *BMJ Open Diabetes Research & Car*, May 2021. DOI: [10.1136/bmjdr-2021-002145](https://doi.org/10.1136/bmjdr-2021-002145)

SOFIA R BARTLETT - CV

15. Janjua NZ, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu P, Samji H, Wilton J, Pearce M, Butt ZA, Yu A, Binka M, **Bartlett S**, Alvarez M, Krajden M. The impact of direct acting antiviral therapies for treatment of HCV on mortality in a large population-based cohort study, Accepted in Journal of Hepatology March 2021 DOI: [10.1016/j.jhep.2021.05.028](https://doi.org/10.1016/j.jhep.2021.05.028)
16. **Bartlett SR**, Buxton J, Palayew A, Picchio CA, Janjua NZ, Kronfli N., Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era. *Clinical Liver Disease*, 2021;17(2): 75-80. DOI: [10.1002/cld.1023](https://doi.org/10.1002/cld.1023)
17. Bonn M, Palayew A, **Bartlett S**, Brothers TD, Touesnard N, Tyndall M, “The Times They Are a-Changin’”: Addressing Common Misconceptions About the Role of Safe Supply in North America’s Overdose Crisis. *Journal of Studies on Alcohol and Drugs*, 2021;82(1): 158-160. DOI: [10.15288/jsad.2021.82.158](https://doi.org/10.15288/jsad.2021.82.158)
18. Kronfli N, Dussault C, **Bartlett SR**, Fuchs D, Kaita K, Jennings L, Barrett L and Cox J. Disparities in hepatitis C care across Canadian provincial prisons: Implications for hepatitis C micro-elimination. *Canadian Liver Journal*, 2021, e20200035. DOI: [10.3138/canlivi-2020-0035](https://doi.org/10.3138/canlivi-2020-0035)
19. Adu P, Rossi C, Wong S, Binka M, Wilton J, Wong J, Butt ZA, **Bartlett SR**, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García H, Krajden M, Janjua NZ. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. *Liver International*, 2021;41(3);482-493 DOI: [10.1111/liv.14762](https://doi.org/10.1111/liv.14762)
20. Pearce M, Yu A, Alvarez M, **Bartlett SR**, Binka M, Jeong D, Clementi E, Adu P, Wilton J, Yoshida E, Pick N, Buxton J, Wong J, Jassem A, Krajden M, Janjua NZ. Prenatal Hepatitis C Screening, Diagnoses, and Follow-Up testing in British Columbia, 2008-2019’. *PLOS ONE*, 2020;15(12), e0244575. DOI: [10.1371/journal.pone.0244575](https://doi.org/10.1371/journal.pone.0244575)
21. Samji H, Yu A, Wong, S, Wilton J, Binka M, Alvarez M, **Bartlett S**, Pearce M, Adu P, Jeong D, Clementi E, Buxton J, Gilbert M, Krajden M, Janjua N. Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada. *International Journal of Drug Policy*, 2020;86 e102989 DOI: [10.1016/j.drugpo.2020.102989](https://doi.org/10.1016/j.drugpo.2020.102989)
22. Bonn M, Palayew A, **Bartlett S**, Brothers TD, Touesnard N, Tyndall M, Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply: *Journal of Studies on Alcohol and Drugs*, 2020;81(5): 556-560. DOI: [10.15288/jsad.2020.81.556](https://doi.org/10.15288/jsad.2020.81.556)
23. Clementi E., **Bartlett S**., Wong S., Yu A., Pearce M., Binka M., Alvarez M., Jeong D., Wilton J., Adu P., Abdia Y., McKee G., Wong J., Butt Z., Krajden M., Otterstatter M., Buxton J., Janjua N., Syndemic profiles of people living with hepatitis C virus using population-level latent class analysis to optimize health services. *International Journal of Infectious Diseases*, 2020; 100: 27-33. DOI: [10.1016/j.ijid.2020.08.035](https://doi.org/10.1016/j.ijid.2020.08.035)
24. Wilton J, Wong S, Yu A, Cook D, Alvarez M, Binka M, Darvishian M, Yoshida E, Ramji A, Krajden M, **Bartlett S**, Pearce M, Adu P, Jeong D, Butt ZA, Janjua NZ. Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection: A population-based cohort study. *Open Forum Infectious Diseases*, 2020; 7(3), ofaa055. DOI: [10.1093/ofid/ofaa055](https://doi.org/10.1093/ofid/ofaa055)
25. **Bartlett SR**, Yu A, Chapinal N, Rossi C, Butt ZA, Wong S, Darvishian M, Gilbert M, Wong J, Binka M, Alvarez M, Tyndall M, Krajden M, Janjua NZ. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of Direct Acting Antivirals, 2019: *Liver International*, DOI: [10.1111/liv.14227](https://doi.org/10.1111/liv.14227)
26. Martinello M, Yee J, **Bartlett SR**, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV. CEASE study

SOFIA R BARTLETT - CV

- team, Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study, 2019: *Clinical Infectious Diseases*, ciz985, DOI: [10.1093/cid/ciz985](https://doi.org/10.1093/cid/ciz985)
27. Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, **Bartlett S**, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Kraiden M, Janjua NZ, Sustained Virologic Response from Interferon-based Hepatitis C regimens IS associated with Reduced risk of Extrahepatic Manifestations, 2019: *Journal of Hepatology*, DOI: [10.1016/j.jhep.2019.07.021](https://doi.org/10.1016/j.jhep.2019.07.021)
 28. Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida E, Wong J, Rossi C, Butt Z, **Bartlett S**, Pearce M, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Kraiden M, Janjua N. Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies, 2019. *Journal of Viral Hepatitis*, DOI: [10.1111/jvh.13228](https://doi.org/10.1111/jvh.13228)
 29. **Bartlett SR**, Kraiden M, Janjua N, Buller-Taylor T. Using population-level integrated health data to monitor and assess patients' progression across care and treatment continuums. *British Columbia Medical Journal*, 2019; 61(2):78-80. <https://bcmj.org/Vol.61/No.2/pages.78,80>
 30. **Bartlett SR**, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews GV, Grebely J. A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004-2015. *Journal of the International AIDS Society*, 2019; 22(2): e25222 DOI:[10.1002/jia2.25222](https://doi.org/10.1002/jia2.25222)
 31. **Bartlett SR**, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, Priscott E, Dore GJ, Russell DB. Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project. *Clinical Infectious Diseases*, 2018; 67(3): 460-463: DOI: [10.1093/cid/ciy210](https://doi.org/10.1093/cid/ciy210)
 32. **Bartlett SR**, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance. *Hepatology Communications*, 2017, DOI: [10.1002/hep4.1050](https://doi.org/10.1002/hep4.1050).
 33. **Bartlett SR**, Wertheim JO, Bull RA, Matthews GV, Lamoury FMJ, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. *Journal of Viral Hepatitis*, 2016; DOI: [10.1111/jvh.12652](https://doi.org/10.1111/jvh.12652).
 34. **Bartlett SR**, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FMJ, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GD, Lloyd A, Grebely J, Applegate TL. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. *Infection, Genetics and Evolution*, 2016; 37:252-258. DOI: [10.1016/j.meegid.2015.11.028](https://doi.org/10.1016/j.meegid.2015.11.028)
 35. Lamoury FMJ, Jacka B, **Bartlett S**, Bull R, Wong A, Amin J, Schinkel J, Poon AF, Matthews GV, Grebely J, Dore GJ, Applegate TL. The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. *PLOSone* 2015; 10:1371. DOI: [10.1371/journal.pone.0131437](https://doi.org/10.1371/journal.pone.0131437)
 36. Lamoury FMJ, **Bartlett S**, Jacka B, Hajarizadeh B, Grebely J, Matthews GV, Dore GJ, Applegate TL. Interferon Lambda 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. *The Journal of Molecular Diagnostics* 2015; 17(5): 583–589. DOI: [10.1016/j.jmoldx.2015.05.003](https://doi.org/10.1016/j.jmoldx.2015.05.003)
 37. **Bartlett S**, Seeliger J, Burnell JN. Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of *Escherichia coli*. *Current Topics in Biochemical Research* 2012; 14(1):77-83. ISSN: [0972-4583](https://doi.org/10.1007/978-1-4939-9458-3)

Full details here: publons.com/sofia-bartlett/

SOFIA R BARTLETT - CV

AUTHORED MANUSCRIPTS UNDER REVIEW

(2 total)

1. Darvishian M; Tang T; Wong S; Binka M; Yu A; Alvarez M; Velásquez García H; Adu P; Jeong D; **Bartlett S**; Karamouzian M; Makuza J; Wong J; Ramji A; Woods R; Krajden M; Janjua N; Bhatti P. Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort. Submitted to International Journal of Cancer, June 2022.
2. Binka M, Adu P, Wong S, Wilton J, Wong J, Butt ZA, **Bartlett SR**, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García H, Ramji A, Yoshida E, Krajden M, Janjua NZ. Lower mortality risk reduction with Entecavir versus Tenofovir treatment for chronic hepatitis B infection. Submitted to Gastroenterology January 2021.

AUTHORED MANUSCRIPTS IN PREPARATION

(3 total)

1. **Bartlett SR**, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ “Hepatitis C Cascade Of Care And Factors Associated With Hepatitis C Treatment Uptake Among People Who Inject Drugs”
2. **Bartlett SR**, Yu A, Pearce M, Binka M, Young S, Sharifi N, Fong M, Wong J, Jessem A, Alvarez M, Buxton J, Krajden M, Janjua NZ.. “Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2011-2021”
3. Snell G, Van Gennip J, Marshall AD, Bonn M, Fuchs D, Yetman G, Butler-McPhee J, Cooper CL, Gallagher L, Kronfli N, Williams S, Bruneau J, Feld JJ, Janjua NZ, Klein M, Grebely J, **Bartlett SR**. “Policies for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada”

AUTHORED REPORTS, GUIDELINES, & POLICY BRIEFS

(5 total)

1. Project Lead & Committee Chair; The You Matter Project: Pathways to care for STBBIs. A guideline and policy recommendations for STBBI testing and linkage to care in BC Provincial Correctional Settings. Published June 2022. ISBN 978-1-7781841-0-9 Available at www.stbbipathways.ca/policies-guidelines/
2. Reviewer; Action Hepatitis Canada. Prison Health Is Public Health: The Right to Hepatitis C Prevention, Diagnosis, and Care in Canada's Correctional Settings. Toronto, ON. March 2022. Available at: <https://www.actionhepatitiscanada.ca/PrisonHealth>
3. Co-author; Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report. Toronto, ON. May 2021. Available at: <https://www.actionhepatitiscanada.ca/progressreport>
4. Reviewer; Clinical Prevention Services. Communicable Disease Control Handbook, Hepatitis C. BC Centre for Disease Control, April 2021. Available at: <http://www.bccdc.ca/Guidelines/HCV.pdf>
5. Reviewer; Clinical Prevention Services. Communicable Disease Control Handbook, Blood and Body Fluid Exposure Management. BC Centre for Disease Control, April 2021. Available at: <http://www.bccdc.ca/Guidelines/BBFE.pdf>

AUTHORED GRANTS & FUNDING

(Total awarded as NPA or Co-PI = \$849,500 CAD)

1. An evaluation of the health, criminal justice and service use outcomes of the Ministry of Health assuming responsibility for prison health care services in BC (PRISM-BC), CIHR Spring 2022 Project Grant CAD \$638,776; Nominated Primary Applicant: Amanda Slaunwhite; **status: Co-Investigator** (awarded)
2. Sustaining Partnerships to Advance Community PrioRities in The IDEAs Cohort (SPARTA), 2022-2024 University of British Columbia Community-University Engagement Support Fund (CUES

SOFIA R BARTLETT - CV

- Fund) Sustain Stream Grant CAD \$24,821; **Nominated Primary Applicant: Dr. Sofia Bartlett** (awarded)
3. COllaboratiNg with peers to improve coNtinuity of hEalth Care during correcTions TransitiONS: The CONNECTIONS Project; 2022-2026 CIHR Transitions in Care Team Grant CAD \$989,960; **Nominated Primary Applicant: Dr. Sofia Bartlett** (under review)
 4. Building capacity to prevent STBBIs in correctional facilities in BC; 2022-2027 Public Health Agency of Canada's (PHAC) HIV and Hepatitis C Community Action Fund (CAF) CAD \$824,018; Nominated Primary Applicant: Amanda Slaunwhite; **status: Co-Investigator** (awarded)
 5. The impact of COVID-19 and related control measures on the hepatitis C virus care cascade; 2022-2023 CIHR Addressing the Wider Health Impacts of COVID-19 CAD \$497,320; Nominated Primary Applicant: Dr. Naveed Janjua; **status: co-applicant** (awarded).
 6. Test, Link, Call (TLC): Transitional care coordination for people living with hepatitis C leaving BC provincial correctional centres; 2021-2022 BCCDC Foundation for Public Health & AbbVie Canada CAD \$124,500; **Nominated Primary Applicant: Dr. Sofia Bartlett** (awarded)
 7. Addressing key knowledge gaps in testing to inform STI prevention & control strategies; 2021-2023 CIHR Project Grant: CAD \$229,500; Nominated Primary Applicant: Dr. Mark Gilbert; **status: Co-Primary Investigator** (awarded)
 8. Canadian Network on Hepatitis C (CanHepC): From Discovery to Implementation; 2021-2025 CIHR Program Grant: Hepatitis C Research CAD \$4.5 mil; Nominated Primary Applicant: Prof Naglaa Shoukry; **status: co-applicant** (awarded)
 9. Characterizing the disease burden from hepatitis B virus in British Columbia, Canada; 2021-2022 CIHR Catalyst Grant: STBBI Research in Canada CAD \$100,000; Nominated Primary Applicant: Dr. Naveed Janjua; **status: co-applicant** (awarded)
 10. Test, Link, Call (TLC): Transitional care coordination for people living with hepatitis C leaving BC provincial correctional centres; 2020-2022 Gilead CONNECT-C Fund CAD \$48,500; **Nominated Primary Applicant: Dr. Sofia Bartlett** (awarded)
 11. Addressing COVID-19 Vaccine concerns AmoNg people who are incarCerated (ADVANCE); 2021-2022 Rapid SARS-CoV-2 Vaccine Research Initiative in BC, CAD \$138,000; **Nominated Primary Applicant: Dr. Sofia Bartlett** (awarded)
 12. Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots (ASSESS-DBS); 2020-2021 BC SUPPORT Unit COVID-19 Research Response Fund CAD \$12,500; Nominated Primary Applicant: Dr Muhammad Morshed; **status: co-applicant** (completed)
 13. Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots (ASSESS-DBS); 2020-2021 COVID-19 Immunity Taskforce (CITF)/Public Health Agency of Canada COVID-19 Research Response Fund CAD \$85,000; Nominated Primary Applicant: Dr Muhammad Morshed; **status: co-applicant** (completed)
 14. Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots (ASSESS-DBS); 2020-2021 MSFHR COVID-19 Research Response Fund CAD \$150,000; Nominated Primary Applicant: Dr Muhammad Morshed; **status: co-applicant** (completed)
 15. Fostering linkage to STBBI care in provincial corrections for people who use drugs; 2020-2022, Public Health Agency of Canada Supporting Pathways to Care for People Who Use Drugs, CAD \$614,457; Nominated Primary Applicant: Dr Naveed Janjua; **status: co-applicant.** (awarded)
 16. Utilizing a syndemic approach for population level prevention, care and treatment cascades of hepatitis C virus and related epidemics; 2018-2020 Canadian Institutes of Health Research &

SOFIA R BARTLETT - CV

Michael Smith Foundation for Health Research Health System Impact Postdoctoral Fellowship; CAD \$155,000 CAD; **Nominated Primary Applicant: Dr Sofia Bartlett** (completed).

17. Hepatitis C virus phylogenetic clustering, transmission networks, and resistance among people who inject drugs: A LiveRLife sub-study; 2017-2018, Merck & Co. Inc Investigator Studies Program (MISP), USD \$70,000, Nominated Primary Applicant: Prof Jason Grebely; **status: co-investigator**. (completed)
18. Molecular epidemiology of recently acquired hepatitis C virus infection in Australia; 2013-2017 Kirby Institute Postgraduate Student Top Up Scholarship, AUD \$45,000, **Nominated Primary Applicant: Dr Sofia Bartlett (completed)**
19. Molecular epidemiology of recently acquired hepatitis C virus infection in Australia; 2013-2017 Australian Postgraduate Award, AUD \$84,000, **Nominated Primary Applicant: Dr Sofia Bartlett (completed)**

TEACHING

2019 – Present	School of Medicine, University of British Columbia, Canada <i>Facilitator</i> ; Responsible Conduct of Research (RCR) course, Semester 2, 2019 <i>Instructor</i> ; PATH417A 99C Human Bacterial Infections undergraduate course, Semester 1, 2020 <i>Guest Lecturer</i> ; MICB 407 Viral Infections in Humans, SPPH 300 Global Health, SPPH 481c Prison Health, PATH 327 Microbial Pathogens
2016 – 2018	School of Biotechnology and Biomolecular Sciences, University of New South Wales, Australia <i>Instructor</i> ; 'Fundamentals Of Biochemistry' (BIOC2181), 'Molecular Cell Biology 1' (BABS2202), 'Biochemistry for Medical students' (MED1)
2010 – 2011	School of Pharmacy & Molecular Sciences, James Cook University, Australia <i>Demonstrator</i> ; Special Topics in Biochemistry and Molecular Biology (BC3202), <i>Instructor</i> ; Principles of Biochemistry (BC2013) <i>Mentor</i> ; Undergraduate Veterinary Sciences program

SELECTED AUTHORED CONFERENCE ABSTRACTS

(55 total, 33 first author)

1. **Bartlett SR**, "Engaging 'prison patient partners' in research on the impact of COVID-19 on prisons" [Panel presentation accepted at Putting Patients First 2022, Virtual, Vancouver, Canada March 10-11].
2. **Bartlett SR**, Yu A, Pearce M, Binka M, Wong J, Alvarez M, Young S, Pick N, Martin RE, Erickson M, Krusi A, Korchinski M, Young P, Fong M, Desrosiers N, Kraiden M, Buxton J, Janjua NZ. "Hepatitis C screening and diagnosis in a Canadian provincial correctional system prior to and during the COVID-19 pandemic" [Poster abstract presented at American Association for the Study of Liver Disease The Liver Meeting, Virtual, United States, November 12-15th, 2021]
3. **Bartlett SR**, Buller-Taylor T, Teal T, Hughes S, Marion T, Korchinski M, Young P, Thomas M, Ellis B, DelRio S, Buxton J, Desrosiers N, Fong M, Beaumont A, Pick N, Erickson M, Jennings L, Luster D, Laird D, Martin RE, Moher M, Krusi A, Young S, Janjua N. "Pathways to hepatitis C care in BC Provincial Corrections: partnering with people in prison to co-create policies and guidelines" [Poster abstract presented at [9th International Symposium on Hepatitis Care In Substance Users](#), Sydney, Australia, October 12-15th, 2021].

SOFIA R BARTLETT - CV

4. **Bartlett SR**, Yu A, Pearce M, Binka M, Wong S, Wong J, Alvarez M, Jessem A, Young S, Pick N, Martin RE, Erickson M, Krusi A, Korchinski M, Young P, Fong M, Desrosiers N, Krajdén M, Buxton J, Janjua NZ. "Increased hepatitis C screening and diagnosis after transfer of health care responsibility to public health system in British Columbia Correctional Centres" [Oral abstract presented at [9th International Symposium on Hepatitis Care In Substance Users](#), Sydney, Australia, October 12-15th, 2021].
5. **Bartlett SR**, Buller-Taylor T, Teal T, Hughes S, Marion T, McMillan B, Buxton J, Sharifi N, Fong M, Beaumont A, Pick N, Erickson M, Jennings L, Luster D, Laird D, Martin RE, Moher M, Krusi A, Young S, Janjua N. "Pathways to hepatitis C care in BC Provincial Corrections: partnering with people in prison to co-create policies and guidelines" [Oral abstract presented at [Canadian Liver Meeting, Virtual, Canada, May 2-5 2021](#)].
6. **Bartlett SR**, Van Gennip J, Marshall AD, Bonn M, Fuchs D, Yetman G, Butler-McPhee J, Cooper CL, Gallagher L, Kronfli N, Williams S, Bruneau J, Feld JJ, Janjua NZ, Klein M, Grebely J. "Policies for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: 'a patchwork of obstruction'" [Poster abstract presented at [Canadian Liver Meeting, Virtual, Canada, May 2-5 2021](#)].
7. **Bartlett SR**, Wong S, Yu A, Pearce M, Binka M, Samji H, Jeong D, Velasquez H, Adu P, Darvishian M, Alvarez M, Cook V, Wong J, Buxton J, Krajdén M, Janjua NZ. Continued inequities in the hepatitis C cascade of care experienced by people who inject drugs in British Columbia in 2019: A population-level linked data study [Poster abstract presented at American Association for the Study of Liver Disease The Liver Meeting, Virtual, United States, November 1st, 2020 DOI: 10.1002/hep.30941]
8. **Bartlett SR**, Yu A, Pearce M, Binka M, Young S, Sharifi N, MacFarlane A, Singleton R, Fong M, Sexsmith M, Wong J, Jessem A, Alvarez M, Buxton J, Krajdén M, Janjua NZ.. "Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019" [Oral abstract presented at Canadian Liver Meeting, Montreal, Canada, March 1st, 2020].
9. **Bartlett SR**, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajdén M, Janjua NZ. "Current Opioid Agonist Therapy is associated with Hepatitis C Virus Treatment Uptake Among People Who Inject Drugs" [Poster abstract presented at Canadian Liver Meeting, Montreal, Canada, March 1st, 2020]
10. **Bartlett SR**, Yu A, Pearce M, Binka M, Young S, Sharifi N, MacFarlane A, Singleton R, Fong M, Sexsmith M, Wong J, Jessem A, Alvarez M, Buxton J, Krajdén M, Janjua NZ.. "Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019" [Poster abstract presented at Canadian Hepatitis C Symposium February 28, 2020].
11. **Bartlett SR**, Pearce M, Schmitz D, Luster D, Krajdén M, Wong J, Yoshida E, Young S, McKee G, Hodgson K, Buxton J, Janjua NZ."Moving towards HepC-FreeBC: A Change Ideas Toolbox" [Poster abstract presented at British Columbia Quality Forum, February 25-27, 2020].
12. **Bartlett SR**, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajdén M, Janjua NZ. "Recent Opioid Agonist Therapy and Hepatitis C Virus Treatment Uptake Among People Who Inject Drugs With Chronic Hepatitis C Infection in a Population Based Data Linkage Study", [Oral Abstract presented at [8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019](#)]
13. **Bartlett SR**, Pearce M, Luster D, Schmitz D, Reitz C, Mazoff CD."Inconsistencies in Methodology, Reporting, And Subjective Description Of Hepatitis C Virus Reinfection Rates Among People Who Inject Drugs: Potential Contribution To Stigma And Discrimination?" [Poster Abstract 007 presented at [8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019](#)]

SOFIA R BARTLETT - CV

14. **Bartlett SR**, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Kraiden M, Janjua NZ. Hepatitis C virus treatment uptake differs according to recency of Opioid Agonist Therapy among people who inject drugs with chronic hepatitis C infection [Poster Abstract 11 presented at [Australasian Viral Hepatitis Elimination Conference, Sydney, Australia, August 12-13, 2019](#)]
15. **Bartlett SR**, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Kraiden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Poster abstract presented at [Canadian Liver Meeting, Montreal, Canada, May 24-26, 2019](#)]
16. **Bartlett SR**, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Kraiden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Oral Poster Abstract ID THU-118 presented at [EASL INTERNATIONAL LIVER CONGRESS \(ILC\), Vienna, Austria, April 10-14, 2019](#)]
17. **Bartlett SR**, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Kraiden M, Janjua NZ. Hepatitis C Cascade Of Care Among People Who Inject Drugs In British Columbia In 2017 [Poster Abstract ID 1782]. [2019 Conference on Retroviruses and Opportunistic Infections \(CROI\), Seattle, Washington March 4-7, 2019.](#)
18. **Bartlett SR**, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Kraiden M, Janjua NZ. Integrating health and administrative datasets to improve quality of care: The BC-HTC [Storyboard presentation ID: 43106]. [British Columbia Quality Forum 2019, Vancouver, Canada February 26-28, 2019.](#)
19. **Bartlett SR**, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Doyle J, Shaw D, Hajkowicz K, Read P, Hellard M, Filep E, Yee J, Martinez M, Lamoury FMJ, Lin L, Dore GJ, Matthews GV. PREVALENCE OF NS5A RESISTANCE ASSOCIATED SUBSTITUTIONS AND HCV DAA TREATMENT OUTCOMES AMONG PEOPLE LIVING WITH HIV IN AUSTRALIA [Oral Abstract 127]. [11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.](#)
20. **Bartlett SR**, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Shaw D, Read P, Hellard M, Filep E, Yee J, Lin L, Martinez M, Lamoury FMJ, Dore GJ, Matthews GV. PHYLOGENETIC CLUSTERING PATTERNS AMONG PEOPLE LIVING WITH HIV AND HEPATITIS C IN AUSTRALIA [Oral Abstract 128]. [11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.](#)
21. **Bartlett SR**, Mala K, Booth TL, Bunde-Birouste A, Stolz A. A community-initiated pilot program using sport to address non-communicable diseases, anti-social behaviour and social inequality [Oral Abstract]. [2018 PNG Update – PNG in the year of APEC, Port Moresby, Papua New Guinea, June 14-15 2018.](#)
22. **Bartlett SR**, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection between 2004-2015, among people with and without HIV co-infection [Oral Abstract]. [6th International Symposium on Hepatitis Care In Substance Users, New York, United States, September 6-8th, 2017.](#)
23. **Bartlett SR**, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection

SOFIA R BARTLETT - CV

- between 2004-2015, among people with and without HIV co-infection [Poster Abstract]. [Australasian Viral Hepatitis Elimination Conference, Cairns, Australia, August 10-11, 2017.](#)
24. **Bartlett SR**, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Methods for sequencing of hepatitis C virus to detect direct-acting antiviral resistance: Systematic review & expert guidance [Oral Abstract]. [12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.](#)
 25. **Bartlett S**, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recently acquired hepatitis C virus infection from 2004-2015 [Oral Abstract 7]. [12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.](#)
 26. **Bartlett SR**, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Bull RA, Ceccherini-Silberstein F, Douglas MW, Dore GD, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance [Poster Abstract THU-303]. [THE INTERNATIONAL LIVER CONGRESS 2017, Amsterdam, the Netherlands, April 19-23, 2017.](#)
 27. **Bartlett S**, Wertheim JO, Bull R, Matthews GV, Lamoury F, Scheffler K, Hellard M, White B, Maher L, Dore GJ, Lloyd AR, Applegate T, Grebely J. Modelling the Effects Of Targeted DAA Hepatitis C Virus Treatment Strategies Using a Molecular Transmission Network Of People with Recent Infection [Oral Abstract]. [10th Australasian Viral Hepatitis Conference, Gold Coast, Australia, September 29th-October 1st, 2016.](#)
 28. **Bartlett S**, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Molecular transmission network of recently acquired HCV in Australia [Oral Abstract 30284]. 11th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Hunter Valley, Australia, December 9-11th, 2015.
 29. **Bartlett S**, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Transmission network of people with recent hepatitis C virus infection in Australia [Poster Abstract]. [22nd International Symposium on Hepatitis C Virus and Related Viruses to be held in Strasbourg, France, October 9-13th, 2015.](#)
 30. **Bartlett S**, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia [Poster Abstract]. [4th International Symposium on Hepatitis Care in Substance Users to be held in Sydney, Australia, October 27-9th 2015.](#)
 31. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic clustering and transmission dynamics of hepatitis C virus infection in Australia [Poster Abstract]. Inaugural EMBL Australia PhD Symposium, UNSW, Australia, December 3rd, 2014.
 32. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic

SOFIA R BARTLETT - CV

clustering of acute hepatitis C virus infection in Australia [Oral Abstract]. [9th Australasian Viral Hepatitis Conference, Alice Springs, Australia, September 17-19th, 2014.](#)

33. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. 21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Canada, September 7-11th, 2014.
34. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia. 19th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, Rome, Italy, September 7-12th, 2014.
35. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. Inaugural Postgraduate Research Symposium, The Kirby Institute, the National Drug and Alcohol Research Centre & the Centre for Social Research in Health, UNSW, Australia, August 29th, 2014.
36. **Bartlett S**, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia [Oral Abstract 6]. 10th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Lorne, Australia, June 4-6th, 2014.

SELECTED INVITED PRESENTATIONS

(23 total)

1. **Invited Guest Speaker**, World Hepatitis Summit (WHS): “Achieving the elimination of viral hepatitis within evolving health systems” June 9, 2022 <https://www.worldhepatitisummit.org/wp-content/uploads/2022/06/Virtual-Programme-with-speakers-v27-WEB.pdf>
2. **Invited Keynote Speaker**, National Collaborating Centre for Infectious Diseases Webcasts Series: “Co-creating policies and guidelines for STBBI care in correctional centres with people who are incarcerated: the You Matter Project”. April 20, 2022 <https://nccid.ca/webcast/co-creating-policies-and-guidelines-for-stbbi-care-in-correctional-centres-with-people-who-are-incarcerated-the-you-matter-project/>
3. **Invited Keynote Speaker**, BC Centre for Disease Control Grand Rounds: “Addressing COVID-19 Vaccine concerns AmoNg people who are incarCerated Study (ADVANCE)”. March 29, 2022 <https://nexuswebcast.mediasite.com/mediasite/Showcase/bc-cdc-showcase/Presentation/398c028d3f3b458e9d6c37156b3eb13a1d>
4. **Invited Keynote Speaker**, British Columbia Liver Rounds: “HCV elimination among people who use drugs & people in prison in BC”. March 9, 2022
5. **Invited Guest Speaker**, Hep C Nurses Empowering Nurses (HEROES) Virtual Regional Nurses Summit: “Linkage to Care for hep C patients”. January 29, 2022
6. **Invited Keynote Speaker**, Vancouver Island HIV Learning Rounds: “Update on HIV and HCV epidemiology in BC & Vancouver Island”. December 10, 2021
7. **Invited Keynote Speaker**, BC Mental Health and Substance Use Services Learning Rounds: “Sexually Transmitted and Blood-Borne Infections among people who are provincially incarcerated in BC: current status and opportunities to enhance care”. December 9, 2021

SOFIA R BARTLETT - CV

8. **Invited Guest Speaker**, Annual Vancouver Liver Forum: “HCV Elimination Workshop: People who use drugs & People in prison”. November 16, 2021
9. **Invited Guest Speaker**, BC Centre for Disease Control Research Week 2021: “The You Matter Project: Partnering With People In Prison To Co-Create STBBI Policies And Guidelines”. October 19, 2021 <https://nexuswebcast.mediasite.com/mediasite/Showcase/bc-cdc-showcase/Presentation/07dbc9357689454fa43f7db8eb3d418d1d/Channel/11560f845de54c4680be2ce8c6b5b7a55f>
10. **Invited Keynote Speaker**, BC Centre for Disease Control World Hepatitis Day Special Webinar: “Why do we need STBBI Policies & Guidelines for Correctional Settings?”. July 28, 2021 <https://vimeo.com/showcase/8788070>
11. **Invited Guest Speaker**, BC COVID Research and Collaboration Symposium: “ASSESS-DBS Study: Mitigating The Impact Of COVID-19 On Marginalized People Through Use Of Dried Blood Spots For SARS-CoV-2 Antibody Testing”. September 1, 2020
12. **Invited Keynote Speaker**, BC Centre for Disease Control Grand Rounds: “Mitigating the impact of COVID-19 on marginalized people: the ‘Accelerating SARS-CoV-2 Sero-prevalence Surveys Through Dried Blood Spots’ (ASSESS-DBS) Study”. July 21, 2020 <https://nexuswebcast.mediasite.com/Mediasite/Showcase/bc-cdc-showcase/Presentation/b131ec44883848678b8b19257039a1f11d>
13. **Invited Guest Speaker**, Pacific AIDS Network (PAN) Presents Webinar: “Research update from the BC-HTC and Community implications”. April 16, 2020 <https://pacificaidnetwork.org/2020/03/20/research-update-bc-htc/>
14. **Invited Keynote Speaker**, British Columbia First Nations Health Authority Educators Forum: “Hepatitis C Infection in BC; Opportunities and Challenges Along the Path to Elimination”. March 3, 2020. <https://pacificaidnetwork.org/files/2020/01/Educators-Forum2020-program-draft.pdf>
15. **Invited Keynote Speaker**, Correctional Services Canada Fraser Valley Institute for Women World Anti-bullying day event: “Staying free from hepatitis C: we’re worth it!”. February 24, 2020.
16. **Invited Keynote Speaker**, Vancouver Lower Mainland Hepatitis Nurse’s Journal Club: “Hepatitis C infection in BC; Opportunities and Challenges Along the Path to Elimination”. December 11th, 2019
17. **Invited Keynote Speaker**: HCV in Correctional Settings Educational Event: “Opportunities & challenges for hepatitis C treatment roll-out in correctional settings”. April 2, 2019.
18. **Invited Guest Speaker**, CATIE’s Hep C Basics Course: “One size does not fit all’ hep C elimination in British Columbia”. February 21, 2019. <https://vimeo.com/319956236>
19. **Invited Keynote Speaker**, The Carnegie Community Centre 25th Annual World AIDS Day Seminar: “Viral Hepatitis in British Columbia; One size does not fit all”. November 29, 2018. <https://pacificaidnetwork.org/files/2018/11/2018-WAD-carnegie.pdf>
20. **Invited Keynote Speaker**, BC Centre for Disease Control Grand Rounds: “Hepatitis C virus micro-elimination among prison populations: demonstration of feasibility and models of care from Australia”. October 2, 2018. <http://mediasite.phsa.ca/Mediasite/Showcase/BCCDC/Presentation/db6c1af017b4d1cafd49b7815af4bb41d>
21. **Invited Keynote Speaker**, Kirby Institute Seminar Series: “Molecular epidemiology of recently acquired hepatitis C virus infection in Australia” Tuesday, 21 November 2017 <https://kirby.unsw.edu.au/event/dr-sofia-bartlett-molecular-epidemiology-recently-acquired-hepatitis-c-virus-infection>
22. **Invited Keynote Speaker**, St Paul University Manila World AIDS Day HIV Update: “Avoid the scare, be aware”. Thursday, 26 January 2017
23. **Invited Keynote Speaker**, Kirby Institute Seminar Series: “Modelling the Effects of Targeted DAA Hepatitis C Virus Treatment Strategies Using a Molecular Transmission Network of People with

SOFIA R BARTLETT - CV

Recent Infection". Tuesday, 29 November 2016 <https://kirby.unsw.edu.au/event/kirby-seminar-ms-sofia-bartlett-modelling-effects-targeted-daa-hepatitis-c-virus-treatment>

24. **Invited Guest Speaker**, Kirby Institute Seminar Series: "*Phylogenetics of recently acquired Hepatitis C virus infection in Australia*". Tuesday, 29 September 2015 <https://kirby.unsw.edu.au/event/kirby-seminar-mr-brendan-jacka-transmission-hepatitis-c-virus-infection-among-younger-and>

SELECTED MEDIA (STORIES, INTERVIEWS, PODCAST EPISODES & BLOG POSTS)

1. Minhas S. Early hepatitis C treatment key to lowering risk of cancer. *BCCDC News*, 2022 July 28. <http://www.bccdc.ca/about/news-stories/stories/2022/world-hepatitis-day-2022>
2. Branch H. World Hepatitis Day 2022. *CIHR Canadian HIV Trials Network News*, 2022 July 28. <https://www.hivnet.ubc.ca/news/2022/07/world-hepatitis-day-2022/>
3. McGrath S. MonkeyPox, People who read live longer than those who don't & World Hepatitis Day. *Global News Radio 980 CKNW Sunday Night Health Show*, 2022 July 24. https://omny.fm/shows/cknw/full-show-monkeypox-people-who-read-live-longer-th?in_playlist=sunday-night-sex-show
4. McGrath S. Roe v. Wade reversed, Urinary tract infection & Hepatitis C. *Global News Radio 980 CKNW Sunday Night Health Show*, 2022 June 26. <https://omny.fm/shows/cknw/full-show-roe-v-wade-reversed-urinary-tract-infect>
5. **Bartlett S**, Santana Parrilla J, Tiwana A. Improving access to Hepatitis C care among people who experience criminalization. *Canadian Observatory on Homelessness Homeless Hub Blog*, 2022 June 20 <https://www.homelesshub.ca/blog/improving-access-hepatitis-c-care-among-people-who-experience-criminalization>
6. **Bartlett S**. Test, Link, Call (TLC) Project: Improving Connection to Hepatitis C Virus Treatment After Release from Provincial Prisons in BC. *BCCDC Foundation for Public Health Blog*, 2022 February <https://bccdcfoundation.org/test-link-call-tlc-project-improving-connection-to-hepatitis-c-virus-treatment-after-release-from-provincial-prisons-in-bc/>
7. Foster M. HCV testing increasing in Canadian correctional centers. *Healio*, 2021 December 16 <https://www.healio.com/news/hepatology/20211217/hcv-testing-increasing-in-canadian-correctional-centers>
8. Piechota I. Then and now: Making advancements in hepatitis care within B.C. correctional settings, *BCMHSUS News*, 2021 October 27 <http://www.bcmhsus.ca/about/news-stories/stories/making-advancements-in-hepatitis-care-within-bc-correctional-settings>
9. Amos H. Bridging the gap: Improving hepatitis care for patients released from correctional facilities. *BCCDC News*, 2021 July 28 <http://www.bccdc.ca/about/news-stories/stories/2021/world-hepatitis-day-2021>
10. Crawford T. COVID-19: Health agencies team up to fund \$1.3 million in vaccine research projects in B.C. *Vancouver Sun*, 2021 May 20 <https://vancouversun.com/news/covid-19-health-agencies-team-up-to-fund-1-3-million-in-vaccine-research-projects-in-b-c>
11. **Bartlett S**. Addressing Barriers to Sexually Transmitted and Blood Borne Infection (STTBI) Screening and Care in Prisons. *BCCDC Foundation for Public Health Blog*, 2021 April <https://bccdcfoundation.org/addressing-barriers-to-sexually-transmitted-and-blood-borne-infection-sttbi-screening-and-care-in-prisons/>

SOFIA R BARTLETT - CV

12. **Bartlett S.** Uncovering SARS-CoV-2 Behind Bars: Understanding the Impact of the COVID-19 Pandemic in Correctional Settings. *BCCDC Foundation for Public Health Blog*, 2021 March <https://bccdcfoundation.org/uncovering-sars-cov-2-behind-bars-understanding-the-impact-of-the-covid-19-pandemic-in-correctional-settings/>
13. Jones AM. New studies to track prevalence of coronavirus antibodies in Canada's prison system amid surge in cases. *CTV News*, 2021 February <https://www.ctvnews.ca/health/new-studies-to-track-prevalence-of-coronavirus-antibodies-in-canada-s-prison-system-amid-surge-in-cases-1.5320065>
14. Daly O. COVID-19 antibody testing at BC Corrections. *BCCDC News*, February 2021 <http://www.bccdc.ca/about/news-stories/stories/2021/covid-19-antibody-testing-at-bc-corrections>
15. **Bartlett S**, Krajden M, Jassem A. New lab process in B.C. simplifying the hepatitis C care cascade. *CATIE BLOG*, 2020 August 17 <http://blog.catie.ca/2020/08/17/new-lab-process-in-b-c-simplifying-the-hepatitis-c-care-cascade/>
16. Hosein S. Progress made in the hepatitis C virus cascade of care but more work lies ahead in B.C. *CATIE News*, 2019 October 17 <https://www.catie.ca/catie-news/progress-made-in-the-hepatitis-c-virus-cascade-of-care-but-more-work-lies-ahead-in-bc>
17. **Bartlett S.** NOhep Supporter Spotlight Canada. *NOhep*, 2019 July 28 <https://www.nohep.org/news-resources/supporter-spotlight-sofia-bartlett/>
18. Volankys R. & Stulpin C. HCV prevalent among US inmates; most are not getting the cure. *Healio*, 2018 November 1 <https://www.healio.com/infectious-disease/hepatitis-c/news/print/infectious-disease-news/%7B4564970f-7c25-4a3f-8509-26d28b89ebce%7D/hcv-prevalent-among-us-inmates-most-are-not-getting-the-cure?page=6>
19. Fazal M. How a Rural Prison Found a Way to Eradicate Hep C. *VICE*, 2018 May 1. https://www.vice.com/en_uk/article/3kimg3/how-a-rural-prison-found-a-way-to-eradicate-hep-c
20. Chapman M. "It's a miracle": Hep C eradicated in prisons thanks to DAAs. *The Limbic*, 2018 April 1. <https://thelimbic.com/gastroenterology/its-a-miracle-hep-c-eradicated-in-prisons-thanks-to-daas/>
21. Dent G. "I see you, I hear you, I believe in you": Ten words that changed Layne Beachley's life. *Women's Agenda*, 2019 March 22 <https://womensagenda.com.au/latest/i-see-you-i-believe-in-you-words-that-changed-layne-beachleys-life/>
22. Viguers S. Unrestricted access to DAAs nearly eliminates HCV in Australian prison. *Healio*, 2018 March 19 <https://www.healio.com/infectious-disease/hepatitis-c/news/online/%7B955dc680-64fc-4a4a-93ab-e91aa338c68d%7D/unrestricted-access-to-daas-nearly-eliminates-hcv-in-australian-prison>
23. Miller C. Deliberate Indifference. *Undisclosed Podcast*, 2017 August <https://undisclosed-podcast.com/episodes/bonus/deliberate-indifference.html>
24. Gorton R. Layne's riding new fashion wave to the stars. *The Daily Telegraph*, 2016 October 1 <https://www.dailytelegraph.com.au/surf-legend-layne-beachley-is-riding-a-new-fashion-wave-to-the-stars>

ACADEMIC SERVICE & NON-PROFIT BOARD MEMBERSHIPS

- 2022- Present** **Co-Director;** Collaborating Centre for Prison Health and Education
- ◆ Lead CCPHE Staff and collaborate with CCPHE members on building partnerships between universities, prisons and the justice system, and

SOFIA R BARTLETT - CV

communities, to reduce disparities that negatively affect those who are in custody or in the process of (re)integrating into society.

2020 - 2021

Steering Committee Member; Action Hepatitis Canada

- ♦ Advised the committee on hepatitis C policy, programming and research issues relevant to the organisations goals and activities
- ♦ Advocated on behalf of people affected by viral hepatitis in Canada at the Provincial and national level

2018 – 2020

Non-Executive Director; HepCBC Hepatitis C Education & Prevention Society, British Columbia, Canada

- ♦ Advised the board on hepatitis C policy, programming and research issues relevant to the organisations goals and activities. Attended community events across Vancouver lower mainland to provide hepatitis C/Blood born virus and sexually transmitted infections education and peer support.

2017 – Present

Co-Founder & Executive Director; Grass Skirt Project Ltd, Australia

- ♦ Senior leadership position involving financial management and organizational strategic decision making. Lead of monitoring and evaluation activities, including development of data collection systems, coordination of data collection team, data analysis and report writing.
- ♦ Involved in preparing government, industry and philanthropic grant proposals, as well as conference abstracts, lay reports and media releases.

2015 – 2017

Committee Member; Kirby Institute Postgraduate Student Seminar Series

- ♦ Curated & organised seminars for postgraduate research students at Kirby Institute. Responsibilities included chairing meetings, taking minutes, sending invitations to guest speakers, moderating panel discussions and promoting events to students within the Kirby Institute.
- ♦ Received UNSW Postgraduate Council Research Student Award in 2016 as recognition for contribution to student life at the institute through the KIPSS seminars.

PROFESSIONAL MEMBERSHIPS

2020- Present	Member, American Association for the Study of the Liver
2019- Present	Member, International Corrections & Prisons Association
2018- Present	Member, Canadian Association for the Study of the Liver
2017- Present	Member, International AIDS society
2016- Present	Member, International Network on Hepatitis for Substance Users

PEER REVIEWING & EDITING

(reviews = 37; papers handled as Assistant Editor = 4)

2022-Current	Reviewer, Open Forum Infectious Diseases (reviews = 1)
2021-Current	Reviewer, Internal Medicine Journal (reviews = 1)
2020-Current	Assistant Editor, BioMed Central Infectious Diseases (papers handled = 4)
2020-Current	Reviewer, BioMed Central Public Health (reviews = 1)

SOFIA R BARTLETT - CV

2020-Current	Reviewer, The Lancet Infectious Diseases (reviews = 1)
2020-Current	Reviewer, Hepatitis Monthly (reviews = 1)
2020-Current	Reviewer, Liver International (reviews = 1)
2019-Current	Reviewer, Canadian Medical Association Journal (reviews = 1)
2019-Current	Reviewer, Canadian Journal of Public Health (reviews = 1)
2018-Current	Reviewer, Journal of Urban Health (reviews = 1)
2018-Current	Reviewer, International Journal of Drug Policy (reviews = 3)
2017-Current	Reviewer, Journal of Viral Hepatitis (reviews = 2)
2017-Current	Reviewer, Infection, Genetics and Evolution (reviews = 3)
2016-Current	Reviewer, Centre for Disease Control Public Health Reports (reviews = 1)
2016-Current	Reviewer, BioMed Central Infectious Diseases (reviews = 12)
2016-Current	Reviewer, PLOSONe (reviews = 2)
2015-Current	Reviewer, Journal of the International AIDS society (reviews = 5)

Full details here: publons.com/sofia-bartlett/

CONFERENCE ORGANISING & REVIEWING

(total reviews = 74)

2022	Abstract reviewer; Annual INHSU Conference (14 reviews)
2022	Organising committee member, Canadian Hepatitis C Symposium
2022	Abstract reviewer, Annual Canadian Liver Meeting (10 reviews)
2021	Abstract reviewer; Annual INHSU Conference (10 reviews)
2020	Abstract reviewer; Annual INHSU Conference (10 reviews)
2019	Abstract reviewer; Australasian Viral Hepatitis Elimination Conference (10 reviews)
2018	Abstract reviewer; Australasian Viral Hepatitis Conference (10 reviews)
2017	Abstract reviewer; Australasian Viral Hepatitis Elimination Conference (10 reviews)

PROFESSIONAL DEVELOPMENT & TRAINING

Provider	Training/Course Name	Date of Completion	Certificate ID
First Nations Information Governance Centre, Algonquin College	Fundamentals of OCAP®	April 7, 2022	NA
Provincial Health Service Authority	Leading Change	October 20th 2021	1FJ6AKAB6
University of British Columbia	Faculty of Medicine Postdoctoral Fellow Enhanced Scholar Program	January 8 th 2020	NA
United Kingdom National Health Service Leadership Academy	School For Change Agents	December 31 st 2019	3r4iv9I

SOFIA R BARTLETT - CV

Canadian Institute of Health Research, Institute of Gender and Health	Core Competency Module for Sex and Gender in the Analysis of Secondary Data from Human Participants	December 2 nd 2019	NA
Dr Julia MacIsaac MD	Shadowing physician while doing OAT, HCV & HBV consults at Alliance Clinic in Surry	November 19 th 2019	NA
Public Health Association of British Columbia	Public Health Summer School: Public Health Approaches & Practice in Complex Systems	July 10 th 2019	NA
San'yas: Indigenous Cultural Safety Training	Core Indigenous Cultural Safety in Health	December 11 th 2018	NA
University of Alberta	Fellowship in Health System Improvement: Political Environment and Managing Health System Performance	November 18 th 2018	NA
Research Project Management	Light-Touch Project Management Workshop	November 7 th 2018	NA
Universite De Geneve	Drugs, drug use, drug policy and health	September 21 st 2018	ZJGCQRZX F2DD
Canadian Institute of Health Research Panel on Research Ethics	Ethical Conduct for Research Involving Humans (TCPS 2: CORE)	August 2 nd 2018	NA
University of New South Wales	Foundations of University Learning & Teaching (FULT)	August 1 st 2016	NA
Italian National Institute for Infectious Diseases "L. Spallanzani"	2014 Virus Evolution and Molecular Epidemiology Workshop (19th VEME)	September 12 th 2014	NA